1. Introduction {#sec1}
===============

Lectins have a carbohydrate recognition domain and exist in nearly all living organisms, ranging from viruses to animals \[[@bib1]\]. Based on their conserved structure and functions, lectins can be categorized into 13 families, including chitinase-like, P-type, C-type, I-type, calnexin/calreticulin, L-type, R-type, F-box lectins, ficolins, intelectins, galectins, M-type, and F-type lectins \[[@bib2]\]. The L-type lectin (LTL) family was the earliest lectin family to be discovered from the seeds of leguminous plants, which contain LTL-like domain\] \[[@bib3]\]. Four kinds of LTLs have been found in mammals: 36 kDa vesicular integral membrane protein (VIP36), ER--Golgi intermediate compartment 53 kDa protein (ERGIC-53), ERGIC-53-like (ERGL) LTL, and VIP36-like (VIPL) LTL \[[@bib4]\]. ERGIC-53 is a cargo receptor for the transport of glycoproteins from the ER to the ERGIC \[[@bib5]\]. In this study, we characterized a novel LTL, a homolog of ERGIC-53, from shrimp *Marsupenaeus japonicus*.

Lectins participate in numerous life processes, including protein synthesis and transport, cell communication, signal transduction, and pathogen recognition \[[@bib6]\]. Pathogen recognition is the first reaction of immunity; lectins consistently function as pattern recognition receptors (PRRs), which can identify pathogen-associated molecular patterns located on the cell surface of pathogens \[[@bib7]\]. LTL functions as a PRR in the immune response of *Macrobrachium nipponense* \[[@bib8]\]. The LTL from *M. japonicus* plays a vital role as an opsonin in antibacterial immune responses \[[@bib9]\]. ERGIC-53 functions as a PRR in the immune system of *Eriocheir sinensis* \[[@bib10]\]. Conversely, ERGIC-53 helps in the replication of infectious arenavirus, coronavirus, and filovirus particles \[[@bib11]\]. A novel L-type lectin is required for the multiplication of white spot syndrome virus (WSSV) in red swamp crayfish *Procambarus clakii* \[[@bib12]\].

WSSV is a member of genus *Whispovirus*, which belongs to the Nimaviridae family. WSSV can infect more than 93 species of shrimp and prawn \[[@bib13]\], including *Litopenaeus vannamei*, *Penaeus monodon*, and *M. japonicas* \[[@bib14]\]. The cumulative mortality of shrimp could approach 100% in 7--10 days after WSSV infection. WSSV causes massive economic damage to shrimp farming worldwide \[[@bib15]\]. WSSV is a capsule-coated virus; its four major envelope proteins, namely, VP24, VP28, VP26, and VP19, can form a protein complex \[[@bib16], [@bib17], [@bib18], [@bib19]\]. VP24, as a chitin-binding protein and the most abundant among the envelope proteins of WSSV, acts as a core protein interacting with other structure proteins and plays an important role in virus assembly and infection \[[@bib20]\]. The absence of VP24 in WSSV-CN04, a new WSSV strain, can attenuate WSSV\'s peroral infectivity \[[@bib21]\]. *LvAMP13.4*, a cuticle protein gene, helps WSSV invade cells by interacting with VP24 \[[@bib22]\]. VP28 is another important structural protein in claw crayfish *Cherax quadricarinatus*. Laminin receptor could bind to VP28 and help WSSV enter the host cell. Loss-of-function of the *CqLR*-like gene can result in strong inhibition of WSSV entry and viral replication \[[@bib23]\].

In this study, we obtained a homolog of LTL from kuruma shrimp, *M. japonicus*, by transcriptome sequencing. This LTL was designated as *Mj*LTL2 (GenBank Accession No. MH094749). *Mj*LTL2 was constitutively expressed in hemocytes, heart, hepatopancreas, gills, stomach, and intestine. *Mj*LTL2 can bind to several Gram-positive (G^+^) and Gram-negative(G^--^) bacteria by binding to their lipopolysaccharide (LPS) and peptidoglycan (PGN). *Mj*LTL2 knockdown can result in lower cumulative mortality and slower WSSV replication. Indeed, this paper is the first to report an L-type lectin from *M. japonicus* that participates in WSSV replication and, thus, provides a new approach to understand the multiplication of WSSV.

2. Materials and methods {#sec2}
========================

2.1. Bacterial and WSSV infection of shrimp and total RNA extraction {#sec2.1}
--------------------------------------------------------------------

Healthy shrimps, approximately 6 cm in length and 7 g in weight, were purchased from Hong-li Seafood Market in Zhifu District, Yantai, Shandong Province, China. The shrimps were cultured in air-pumped artificial seawater at 24 °C for 1 week prior to the experiments. Three shrimps were selected randomly for tissue (hemocytes, heart, hepatopancreas, gill, stomach, and intestine) collection to extract RNA. Hemolymph was extracted from the ventral sinus of shrimp using a 5 ml syringe containing 1 ml of anticoagulant (450 mM NaCl, 10 mM KCl, 10 mM EDTA, and 10 mM HEPEs, pH 7.0) and centrifuged at 800×*g* for 5 min at 4 °C for hemocyte collection. Subsequently, the supernatant was discarded and 1 ml of Trizol was added to resuspend the hemocytes. The five other tissue samples, namely, heart, hepatopancreas, gills, stomach, and intestine, were dissected using a forfex and tweezers, ground using a homogenizer with 1 ml of Trizol, and transferred to five 1.5 ml RNase-free centrifuge tubes. In total, six centrifuge tubes were marked and centrifuged at 12,000×*g* for 10 min at 4 °C to remove impurities. Afterward, the supernatant was transferred into new 1.5 ml RNase-free centrifuge tubes, and phenol/chloroform (v/v = 1:1) was added. The solution was shaken, stand still for 5 min, and then centrifuged at 12,000×*g* for 10 min at 4 °C. The supernatant was carefully transferred into new RNase-free centrifuge tubes, added with 800 μl of isopropyl alcohol, shaken, stand still for 20 min, and then centrifuged at 12,000×*g* for 10 min at 4 °C. The supernatant was discarded, and 1 ml of 75% ethanol was added to the tube. The sediment was resuspended and centrifuged at 7500×*g* for 10 min at 4 °C. The resultant supernatant was discarded, and the remaining sediment was air dried and added with 20 μl of RNase-free water.

*M. japonicus* individuals used for the WSSV challenge were randomly divided into the challenge group and the control group. The WSSV inoculum was acquired according to previous publications \[[@bib24]\]. All tissues of WSSV-infected shrimp were homogenized in sterile phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 2 mM KH~2~PO~4~, 10 mM Na~2~HPO~4~, pH 7.4) at a ratio of 10% (w/v). The supernatant was filtered through a 0.45 nm filter after centrifugation at 3000×*g* for 5 min at 4 °C. The virus titer was determined by quantitative real-time polymerase chain reaction (qRT--PCR) \[[@bib25]\]. Each shrimp in the challenge group was injected with 30 μl of WSSV inoculum (1 × 10^5^ virions), and shrimps in the control group were injected with 20 μl of PBS. *M. japonicus* individuals used for the *V. anguillarum* challenge were randomly divided into two groups similar to the WSSV challenge. Shrimps in the challenge group were injected with 10^7^ CFU of *V. anguillarum* in 50 μl of PBS, while shrimps in the control group were injected with 50 μl of PBS. The *V. anguillarum* titer was determined according to previous publications \[[@bib26]\]. Hemocytes and hepatopancreas were collected from at least three individuals randomly selected from both groups 12, 24, 36, and 48 h after injection of WSSV and 6, 12, and 24 h after injection of *V. anguillarum* for RNA extraction.

Total RNA was extracted using Unizol reagent (Biostar, Shanghai, China) according to the method described above. cDNA was reverse transcribed using the SMART cDNA kit (Clontech, Santa Clara, CA, USA) with primers Oligo-anchor R and Smart F ([Table 1](#tbl1){ref-type="table"} ) following the manufacturer\'s instructions.Table 1Sequences of the primers used in this study.Table 1PrimerSequence (5′--3′)DirectionPositionMjLTL2-RTFAGTGGAATGGGTTGGGTGTGTForward383--403MjLTL2-RTRTAGTTGCTGGCTTAGTCCATCGTGTReverse492--516Smart FTACGGCTGCGAGAAGACGACAGAAGGGMjLTL2-EXFTACTCAGGATCCAGACGCTTCGAATATAAGTACAGTTTCForward85--115MjLTL2-EXRTACTCACTCGAGTTACGACCTCAGGGACGTCACAAGGAACReverse738--762MjLTL2-RiFTAATACGACTCACTATAGGCCTACGAACTTTGAATGGTGGGForward247--268MjLTL2-RiRTAATACGACTCACTATAGGAGTGGCAGCCGAGATTCCAAAGTATReverse681--705GFPiFGCGTAATACGACTCACTATAGGTGGTCCCAATTCTCGTGGAACForwardGFPiRGCGTAATACGACTCACTATAGGCTTGAAGTTGACCTTGATGCCReverseactinFAGTAGCCGCCCTGGTTGTAGACactinRTTCTCCATGTCGTCCCAGT

2.2. Phylogenetic and sequence analyses of MjLTL2 {#sec2.2}
-------------------------------------------------

Putative amino acid sequences of *Mj*LTL2 were generated and protein domain was predicted using the online programs of ExPASy (<http://www.au.expasy.org/>) and SMART (<http://smart.embl-heidelberg.de/index2.cgi>), respectively. LTLs were retrieved and selected in the NCBI GenBank database to analyze the evolutionary relationship of *Mj*LTL2 with other LTLs. Sequence alignment was conducted based on amino acid sequences using MEGA 5.1 and GENEDOC, and a phylogenetic tree was thereby constructed using MEGA 5.1. Phylogenetic analysis was conducted according to previous publications \[[@bib27]\]. One thousand bootstraps were performed for the neighbor-joining (NJ) trees to evaluate the reproducibility of the results.

2.3. Detection of MjLTL2 distribution by qRT--PCR {#sec2.3}
-------------------------------------------------

Transcriptional levels of *Mj*LTL2 in hemocytes, heart, hepatopancreas, gills, stomach, and intestine were detected by qRT--PCR using the primer pair *Mj*PLTL2-RTF/*Mj*LTL2-RTR ([Table 1](#tbl1){ref-type="table"}). Here, *β-actin* was used as the internal control for primers actin F and actin R ([Table 1](#tbl1){ref-type="table"}). PCR was conducted under the following conditions: one cycle at 94 °C for 3 min; 28 cycles each at 94 °C for 30 s, at 59 °C for 30 s, and at 72 °C for 30 s; and one cycle at 72 °C for 5 min *Mj*LTL2 expression levels were examined by the comparative CT method, and qRT-PCR data were analyzed by the 2^−ΔΔCT^ method. Unpaired Student\'s *t*-test was used for statistical analysis.

2.4. Time-course expression profiles of MjLTL2 {#sec2.4}
----------------------------------------------

The expression profiles of *Mj*LTL2 after immune challenge were determined by qRT--PCR using a C1000TM thermal cycler (Bio-Rad, Hercules, USA) with *β-actin* as internal control. The total volume was 10 μl, including 5 μl of 2 × Premix Ex Taq, 1 μl of cDNA template (diluted to 1:50), and 2 μl of the forward and reverse primers (1 μM). The amplification conditions were as follows: 95 °C for 3 min; 40 cycles each at 95 °C for 30 s, at 59 °C for 15 s, and at 72 °C for 15 s; template reading at 76 °C for 2 s; and a final melting curve from 60 °C to 95 °C. Amplification was repeated thrice for qPCR analysis. qRT--PCR data were analyzed by the 2^−ΔΔCT^ method \[[@bib28]\], and statistical analysis was conducted using unpaired Student\'s *t*-test. A difference of p \< 0.05 was considered statically significant.

2.5. Recombinant expression and purification of MjLTL2 and PET30A in *Escherichia coli* {#sec2.5}
---------------------------------------------------------------------------------------

cDNA fragments of *Mj*LTL2 were amplified with specific primers (*Mj*LTL2 ExF and *Mj*LTL2 ExR) containing endonuclease sites of *Bam*H I and *Xho*I, as shown in [Table 1](#tbl1){ref-type="table"}. The cDNA fragment was ligated to pET30a (+) vector (digested with *Bam*H I and *Xho* I) with T4 ligase (Takara Dalian, China). Expression plasmids (pET30a-*Mj*LTL2) were transformed into *Escherichia coli* BL21 (DE3). Recombinant protein was induced by 0.4 mM isopropyl b-d-1-thiogalactopyranoside (IPTG) at 37 °C.

Recombinant proteins were expressed as inclusion bodies and purified as previously described \[[@bib29]\]. The PET30A (with His-tag) protein was also expressed and purified for control experiments. The empty pET30a vector was transformed into *E. coli* BL21 (DE3), and its expression was induced by 0.4 mM IPTG at 37 °C. The expressed soluble PET30A was then purified by His-Bind resin chromatography.

2.6. Preparation of MjLTL2 antiserum and western blot analysis {#sec2.6}
--------------------------------------------------------------

The purified recombinant *Mj*LTL2 protein was used as an antigen for antiserum preparation in accordance with the protocol described by Du et al. (2007) \[[@bib30]\]. Western blot analysis was performed as previously described (Nufer et al., 2003) using anti-*Mj*TLT2 as the first antibody \[[@bib31]\].

2.7. Bacterial agglutination assay {#sec2.7}
----------------------------------

G^+^ bacteria (*Bacillus subtilis, Bacillus megaterium, Bacillus thuringiensis, Micrococcus luteus, and Staphylococcus aureus*) and G^--^ bacteria (*E. coli, Pseudomonas aeruginosa, and V. anguillarum*) were used in this assay. Agglutination assay was performed following a previously described method \[[@bib32]\]. In brief, bacteria in mid-logarithmic phase were collected by centrifugation at 6000×*g* for 5 min and resuspended in Tris-buffered saline (TBS) (0.15 M NaCl, 0.01 M Tris--HCl, pH 7.5). The bacteria were then washed thrice with TBS, and the bacterial concentration used for agglutination assay was adjusted to 0.4 OD600 using TBS. The original concentration of the recombinant *Mj*LTL2 (r*Mj*LTL2) was 1.6 mg/ml and serially diluted twice. Microorganisms were incubated with r*Mj*LTL2 in 10 mM CaCl~2~ at room temperature for 1 h, and agglutinating reactions were observed under a microscope (Nikon ECLIPSE TE2000-U, Japan). PET30A was used as control.

2.8. Bacterial binding assay {#sec2.8}
----------------------------

The bacteria used in this assay were identical to the bacteria used in the agglutination assay. Exactly 4 μl of the purified r*Mj*LTL2 (2 μg/μl) was incubated with the aforementioned microorganisms for 30 min at room temperature with rotation. Microorganisms were collected by centrifugation (6000×*g* for 5 min), washed four times with TBS, and eluted with 10% sodium dodecyl sulfate (SDS). The supernatant from different bacteria was used for SDS--polyacrylamide gel electrophoresis (SDS--PAGE) and immunoblotting analysis with anti-*Mj*LTL2 as the first antibody.

2.9. Carbohydrate-binding specificity assay {#sec2.9}
-------------------------------------------

Several carbohydrates, LPS, PGN, lipoteichoic acids (LTAs), trehalose, [d]{.smallcaps}-mannose, glucose, and N-acetyl galactosamine were used to inhibit the binding activity of *Mj*LTL2 to *B. subtilis* cells. The recombinant protein *Mj*LTL2 was first incubated with 50 μl of carbohydrate (gradient concentration from 0.5 mg/ml to 20 mg/ml) for 1 h at room temperature. Then, 10 μl of *B. subtilis* (2 × 10^7^ cells/ml) and CaCl~2~ (final concentration of 5 mM) were added to the tube and incubated at room temperature for 1 h. Agglutination reactions were observed under a microscope. Enzyme-linked immunosorbent assay was applied to test the carbohydrate-binding specificity of *Mj*LTL2. PGN, LPS, LTA, and mannose were used for this assay. Each saccharide was dissolved in water at 80 mg/ml and sonicated thrice for 15 s. Then, 50 ml (4 mg) of polysaccharide was added to each well of a microtiter plate. The plate was incubated at 37 °C for 12 h to evaporate the solution and then heated at 60 °C for 30 min. The wells of the plate were blocked with 200 ml/well of bovine serum albumin (BSA) (1 mg/ml) in TBS for 2 h at 37 °C. The plates were washed four times with TBS, and 50 μl of various concentrations of recombinant protein (0--50 μg/ml dissolved in TBS in 0.1 mg/mL BSA) was added to the wells. Afterward, the plates were incubated at room temperature for 3 h and washed. The antiserum of *Mj*LTL2 (1:400 dilution) was added to each well and incubated for 1 h at 37 °C. The wells were washed four times with TBS. Peroxidase-conjugated goat anti-rabbit IgG (2000 × dilution) was added to each well and incubated for 1 h at 37 °C. The wells were washed four times as previously described, and color was developed by adding 0.01% 3,30,5,50-tetramethylbenzidine (Sigma) liquid substrate to each well. Coloration was stopped with 2 M H~2~SO~4~, and the absorbance was read at 450 nm. Control experiments were performed using PET30A instead of r*Mj*LTL2. The assay was repeated thrice. Dissociation constants and maximum binding parameters were calculated using GraphPad Prism version 5.00 software for Windows (San Diego, CA,USA).

2.10. Bacterial clearance assay {#sec2.10}
-------------------------------

Bacterial clearance assay was performed to analyze the function of *Mj*LTL2 in vivo. r*Mj*LTL2 (20 μg) was incubated with *V. anguillarum* (2 × 10^8^ CFU/ml) at 37 °C for 0.5 h in the presence or absence of Ca^2+^ (5 mM), and PET30A with or without Ca^2+^ were used as controls. After incubation, bacteria (50 μl) were injected into the shrimp. Hemolymph was extracted 2, 5, and 30 min post-injection and diluted 10,000 × . The diluted hemolymph (50 μl) was loaded on lysogeny-broth agar plates. The plates were incubated at 37 °C for 12 h, and the number of bacterial colonies was counted. For each group, three shrimp were used. After qRT--PCR analysis, the data obtained were presented as the mean ± SD of three independent experiments and statistically analyzed using Student\'s *t*-test. Significant differences were accepted at p \< 0.05.

2.11. RNA interference (RNAi) assay {#sec2.11}
-----------------------------------

RNAi assay was performed for functional analysis of *Mj*LTL2 in WSSV duplication with *dsGFP* and PBS serving as controls. *Mj*LTL2 dsRNA was synthesized as follows. Specific primers, namely, *Mj*LTL2-RiF and *Mj*LTL2-RiR ([Table 1](#tbl1){ref-type="table"}), were used to amplify the template cDNA; these primers were approximately 500 bp and located within the open reading frame (ORF) of *Mj*LTL2. A total weight of 2.5 μg of the templates was added to each tube for RNA synthesis; each tube also contained 0.24 μM nucleoside triphosphate (Fermentas), 80 U of T7 polymerase (Fermentas), 10 μl 5 × transcription buffer (Fermentas), 80 U of RiboLock (Thermo Scientific), and 13 μl of RNase-free water. The tubes were incubated in a water bath for at least 7 h at 37 °C for RNA synthesis, followed by addition of 8 U of DNase1 (Fermentas) and 32 μl of 10 × reaction buffer supplemented with MgCl~2~ and RNase-free water. Tubes with a total volume of 100 μl were incubated in a water bath for approximately 1 h at 37 °C for DNA template digestion. Afterward, the synthesized dsRNA was extracted using phenol and chloroform, precipitated with ethanol, air dried, and dissolved in RNase-free water. dsRNA concentrations were detected by a NanoDrop® ND-1000 instrument (NanoDrop, USA). *dsGFP* was synthesized using primers GFPiF and GFPiR ([Table 1](#tbl1){ref-type="table"}) according to the aforementioned method with *GFP* cDNA as the template.

A total of 45 healthy *M. japonicus* measuring 4--5 cm and weighing 3.5--4.5 g were randomly divided into three groups, namely, the *dsMj*LTL2, *dsGFP*, and PBS groups. All shrimps in the *dsMj*LTL2 and *dsGFP* groups were injected with 10 μg of dsRNA, while those in the PBS group were injected with 10 μl of PBS. A second injection was performed 24 h later. The efficiency of *Mj*LTL2 was detected through qRT-PCR with the primer pairs *Mj*LTL2-RTF/*Mj*LTL2-RTR.

2.12. Time--mortality assay after MjLTL2 knockdown {#sec2.12}
--------------------------------------------------

After *Mj*LTL2 knockdown, shrimps in the challenge group were injected with WSSV at a dose of 3.0 × 10^7^ in 20 μl PBS, while those in the control group were injected with 20 μl of PBS. Mortality was recorded at 8:00 p.m. every day for 1 week starting from the day after injection.

2.13. Time-course expression profiles of VP19, VP24, VP26 and VP28 after MjLTL2 knockdown {#sec2.13}
-----------------------------------------------------------------------------------------

After *Mj*LTL2 knockdown and WSSV injection, hemocytes were collected 36 and 48 h post-injection (hpi) from at least three shrimp for RNA extraction. The expression profiles of *VP19, VP24, VP26,* and *VP28* were detected by qRT--PCR.

3. Results {#sec3}
==========

3.1. Phylogenetic analyses of MjLTL2 {#sec3.1}
------------------------------------

A homolog of L-type lectin was identified from *M. japonicus* using genome sequencing. This homolog belongs to the lectin L-type super family. The obtained cDNA of *Mj*LTL2 has a length of 1585 bp and an ORF of 1518 bp and encodes a protein of 505 amino acids (GenBank Accession No. MH 094749). *Mj*LTL2 contained a signal peptide of 24 residues from amino acids 1--24 ([Fig. 1](#fig1){ref-type="fig"} ), a Lectin_leg-like domain from amino acids 29--254, a coiled coil from amino acids 261--293, and a transmembrane domain from amino acids 471--493. The theoretical isoelectric point and molecular mass of the mature *Mj*LTL2 were 6.01 and 57044.32 Da, respectively.Fig. 1*Mj*LTL2 has a signal peptide, Lectin_leg-like domain, coiled coil, and transmembrane domain.Fig. 1

Phylogenetic analysis of *Mj*LTL2 with other selected LTLs ([Fig. 2](#fig2){ref-type="fig"} ) revealed that LTLs from different organisms could be divided into two large groups: aquatic invertebrate LTLs and terrestrial invertebrate LTLs. MjLTL2 and *Eriocheir sinensis* LTL were grouped into one branch (see [Fig. 2](#fig2){ref-type="fig"}).Fig. 2**Phylogenetic analyses of *Mj*LTL2.** Phylogenetic trees was constructed using MEGA 7.0 software with a bootstrap value of 1000. The bar indicates the genetic distance. *Mj*LTL2 is marked by the black square.Fig. 2

Multiple alignment of amino acid sequences of LTLs from *M. japonicus* and 58 other animals indicated that conserved amino acid residues are mainly located in the amino terminal of the chosen LTLs and *Mj*LTL2, where the Lectin_leg-like domain is found ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3**Multiple alignment of amino acid sequences of LTL from *M. japonicus* and other animals**. 1, *Eriocheir sinensis* AIM 45537; 2, *Hyalella azteca* XP 018018316; 3, *Orussus abietinus* XP 012275732; 4, *Diachasma alloeum* XP 015111008; 5, *Fopius arisanus* XP 011301413; 6, *Daphnia pulex* EFX 88628; 7, *Neodiprion lecontei* XP 015512379; 8, *Athalia rosae* XP 012257383; 9, *Tribolium castaneum* XP 971530; 10, *Linepithema humile* XP 012221854; 11, *Zootermopsis nevadensis* XP 021920325; 12, *Centruroides sculpturatus* XP 023226933; 13, *Harpegnathos saltator* XP 011154813; 14, *Nasonia vitripennis* XP 016841495; 15, *Ooceraea biroi* XP 011335262; 16, *Dinoponera quadriceps* XP 014474950; 17, *Anoplophora glabripennis* XP 018562836; 18, *Nicrophorus vespilloides* XP 017772508; 19, *Onthophagus taurus* XP 022911466; 20, *Wasmannia auropunctata* XP 011689358; 21, *Vollenhovia emeryi* XP 011862743; 22, *Limulus polyphemus* XP 013776768; 23, *Cryptotermes secundus* XP 023725174; 24, *Temnothorax curvispinosus* XP 024872030; 25, *Trachymyrmex zeteki* XP 018314383; 26, *Monomorium pharaonis* XP 012540603; 27, *Megachile rotundata* XP 003704272; 28, *Dufourea novaeangliae* XP 015437435; 29, *Polistes dominula* XP 015186950.Fig. 3

3.2. MjLTL2 expression was upregulated by WSSV or V. anguillarum challenge {#sec3.2}
--------------------------------------------------------------------------

Total RNA was extracted from six tissues, namely, hemocytes, heart, hepatopancreas, gill, stomach, and intestine, and detected by qRT--PCR to examine the distribution of *Mj*LTL2 mRNA in *M. japonicus*; here, *β-actin* was used as the control. The qRT-PCR results suggested that *Mj*LTL2 is ubiquitously distributed in all tested tissues, with relatively higher expression in hemocytes and the hepatopancreas than in other tissues ([Fig. 4](#fig4){ref-type="fig"} A).Fig. 4**Temporal and spatial expression profiles of *Mj*LTL2.** (A) Tissue distribution of *Mj*LTL2. Expression profiles of *Mj*LTL2 in hemocytes (B) and the hepatopancreas (C) of shrimps after injection of WSSV were analyzed by qRT--PCR. Expression profiles of *Mj*LTL2 in hemocytes (D) and the hepatopancreas (E) of shrimps after injection of *V. anguillarum* were analyzed by qRT--PCR. PCR was normalized by β-actin expression. \*, p \< 0.05. Error bars represent the SD of three replicates.Fig. 4

The temporal expression profiles of *Mj*LTL2 in hemocytes and the hepatopancreas of WSSV- or *V. anguillarum-*challenged shrimps were also analyzed, and results indicated that *Mj*LTL2 expression is upregulated 24--48 h after WSSV injection in hemocytes and the hepatopancreas ([Fig. 4](#fig4){ref-type="fig"}B and C); by comparison, *Mj*LTL2 is upregulated 6--24 h after *V. anguillarum* injection ([Fig. 4](#fig4){ref-type="fig"}D and E). These results reveal the potential role of *Mj*LTL2 in the immunity of shrimp.

3.3. Recombinant *Mj*LTL2 could agglutinate bacteria {#sec3.3}
----------------------------------------------------

The L-type lectin domain of *Mj*LTL2 was expressed in *E. coli* BL21 (DE3) ([Fig. 5](#fig5){ref-type="fig"} A). We performed agglutination assay using G^+^ and G^--^ bacteria to test whether r*Mj*LTL2 can agglutinate microorganisms. The results showed that r*Mj*LTL2 can agglutinate several G^+^ (S*. aureus, B. megaterium, B. subtilis, B. thuringiensis,* and *M. luteus*) and G^--^ (*E. coli, P. aeruginosa,* and *V. anguillarum*) ([Fig. 5](#fig5){ref-type="fig"}B) bacteria. Moreover, the agglutinating activity of r*Mj*LTL2 is not Ca-dependent.Fig. 5**Recombinant *Mj*LTL2 could agglutinate different bacteria.** (A) SDS--PAGE analysis of recombinant *Mj*LTL2 and PET30A expressed in *E. coli* BL21 (DE3). Lane M, protein marker; lanes 1 and 4, noninduced *E. coli* with PET30A-LTL2 or PET30A; lanes 2 and 5, induced *E. coli* with PET30A-LTL2 or PET30A by IPTG; lanes 3 and 6, purified recombinant *Mj*LTL2 or PET30A. (B) Bacterial agglutination by r*Mj*LTL2. Gram-positive *B. subtilis* was used for the agglutination assay, and PET30A was used as a control. The experiment was repeated three times.Fig. 5

The minimal agglutinating concentrations of r*Mj*LTL2 are shown in [Table 2](#tbl2){ref-type="table"} .Table 2Minimal agglutinating concentrations of r*Mj*LTL2.Table 2BacteriaMinimum agglutination concentration(μg/ml)*S.aureus*1.65*B.megaterium*1.65*E.coli*1.65*B.subtilis*3.3*P.aerugillarum*1.65*V.anguillarum*3.3*B.thuringiensis*1.65*M.luteus*1.65

3.4. r*Mj*LTL2 could bind different bacteria and polysaccharides {#sec3.4}
----------------------------------------------------------------

A bacterial binding assay was performed to test whether r*Mj*LTL2 could bind to microorganisms. The results showed that r*Mj*LTL2 could bind to several G^--^ (*P. aeruginosa, V. anguillarum,* and *E. coli*) and G^+^ (*S. aureus, B. thuringiensis, B. subtilis, B. megaterium,* and *M. luteus*) bacteria ([Fig. 6](#fig6){ref-type="fig"} A).Fig. 6***Mj*LTL2 binds to bacteria and polysaccharides.** (A) Binding activity of r*Mj*LTL2 to different bacteria detected by Western blot using anti-*Mj*LTL2 as the first antibody. (B) Binding activity of PET30A (control) to different bacteria. (C) Direct binding activity of r*Mj*LTL2 to polysaccharides, LTA, LPS, and PGN. Data are shown as the mean ± SE of three experiments.Fig. 6

Direct binding assay to saccharides was performed. The results showed that r*Mj*LTL2 could directly bind to LPS, PGN, and LTA with different binding affinities ([Fig. 6](#fig6){ref-type="fig"}C).

Indirect binding assay to carbohydrates was performed. Eight saccharides, including monosaccharides (trehalose, [d]{.smallcaps}-mannose, glucose, N-Acetyl galactosamine, and sucrose) and polysaccharides (LTA, PGN, and LPS) were used for the inhibitory agglutination of *B. subtilis* cells. The results showed that LTA, LPS, and PGN could inhibit the agglutinating activity of r*Mj*LTL2 at different concentrations and that no monosaccharide could inhibit the agglutinating activity of r*Mj*LTL2 at a concentration of 800 mM ([Table 3](#tbl3){ref-type="table"} ).Table 3Inhibition effects of carbohydrates on the agglutinating activity of r*Mj*LTL2.Table 3CarbohydrateMinimum concentrationLTA1.25 mg/mlLPSNⅠ^a^PGNNⅠ^b^ThehaloseNⅠ^b^[d]{.smallcaps}-mannoseNⅠ^b^GlucoseNⅠ^b^N-Acetly galacto samineNⅠ^b^SucroseNⅠ^b^[^1][^2]

3.5. MjLTL2 knockdown lowered the cumulative mortality of *M. japonicus* upon WSSV infection {#sec3.5}
--------------------------------------------------------------------------------------------

Time--mortality assay was performed to test the significance of *Mj*LTL2 to shrimp during WSSV infection. The cumulative mortality of the three batches of shrimps (*dsMj*LTL2, *dsGFP*, and PBS groups) presented different variation trends ([Fig. 7](#fig7){ref-type="fig"} B) after *Mj*LTL2 knockdown ([Fig. 7](#fig7){ref-type="fig"}A). Specifically, cumulative shrimp mortality displayed distinct patterns among the three groups, which was elevated from 1 dpi to 7 dpi in the *dsGFP* and PBS groups compared with that in the *dsMj*LTL2 group. These results suggest that *Mj*LTL2 may participate in WSSV proliferation \[[@bib25]\].Fig. 7**Time--mortality assay was performed after *Mj*LTL2 silencing.** (A) *Mj*LTL2 knockdown in hemocytes by injection with *Mj*LTL2 dsRNA; dsGFP injection as used as the control. Error bars represent the SD of three replicates. (B) Shrimps were injected with WSSV after *Mj*LTL2 silencing, and mortality was calculated on days 1, 2, 3, 4, 5, 6, and 7; *dsGFP* and PBS injection were used as controls. \*, p \< 0.05, \*\*, p \< 0.01. Error bars represent the SD of three replicates.Fig. 7

3.6. MjLTL2 is essential for the expression of VP19, VP24, VP26, VP28 {#sec3.6}
---------------------------------------------------------------------

The time--mortality change curves indicated that *Mj*LTL2 may take part in WSSV replication. Thus, whether WSSV envelope protein expression is affected by *Mj*LTL2 knockdown was directly assessed ([Fig. 8](#fig8){ref-type="fig"} ). Here, *dsGFP* injection was used as a mock control, and PCR was normalized by *β-actin* expression. Our results revealed lower *VP19, VP24, VP26,* and *VP2*8 mRNA expression in the hemocytes of *Mj*LTL2 knockdown shrimps than in the control. In addition, *VP19, VP24, VP26,* and *VP28* expression increased continually from 36 hpi to 48 hpi.Fig. 8**Relative changes in *VP19, VP24, VP26,* and *VP28* expression.** Shrimps were injected with WSSV after *Mj*LTL2 silencing, followed by total RNA extraction from hemocytes at 36 and 48 hpi. The expression profiles of *VP19, VP24, VP26,* and *VP28* were analyzed using qRT--PCR, with *dsGFP* injection as the control. PCR was normalized by β-actin expression. \*, p \< 0.05. Error bars represented the SD of three replicates.Fig. 8

4. Discussion {#sec4}
=============

In the present study, we cloned and characterized a novel ERGIC-53 lectin, named *Mj*LTL2, from kuruma shrimp *M. japonicus*. Expression of *Mj*LTL2 was upregulated by *V. anguillarum* challenge; the lectin could also agglutinate bacteria without the presence of Ca^2+^ and bind to several bacteria by binding to LTA, PGN, and LPS. However, no evidence yet confirms that *Mj*LTL2 is directly involved in antibacterial immunity (data of bacterial clearance assay are not shown). Although *Mj*LTL2 is not directly involved in anti-bacterial immunity, it may participate in WSSV replication.

The results of this study revealed that expression of *MjLTL2* was upregulated from 24 to 48 hpi in hemocytes and hepatopancreas after WSSV injection. In the presence of WSSV infection, *MjLTL2* knockdown resulted in the 7-day lower cumulative mortality of *M. japonicus* compared with the control. We thus speculate that viral replication in the *dsMjLTL2* injection group was slower than that in the control. Further research showed that less *VP19*, *VP24*, *VP26*, and *VP2*8 mRNA could be extracted from hemocytes of *MjLTL2* knockdown shrimp than from the control group. Taken together, these results suggest that *Mj*LTL2 is important for WSSV replication.

The relationship between WSSV infection and the host\'s immune response hasn\'t been fully revealed yet. A suppression subtractive hybridization cDNA library was used to identify differentially expressed genes in WSSV-infected shrimp *Penaeus monodon*. Many genes either inhibit viral replication or facilitate viral pathogenesis \[[@bib33]\]. Endonuclease-reverse transcriptase in *M. japonicus* promotes anti-WSSV immunity by regulating superoxide dismutase activity, apoptosis, and phenoloxidase activity \[[@bib34]\]. The *Lvc-Jun* gene could upregulate the activity of the *wsv249* promoter to facilitate viral replication \[[@bib35]\]. WSSV can regulate host immunity and take advantage of miR-S5 to regulate hemocyte phagocytosis and apoptosis \[[@bib36]\]. *Wsv187*, which is encoded by the WSSV immediate early gene, activates the host\'s JAK/STAT pathway for replication \[[@bib37]\]. Additionally, *wsv249* encodes an E3 ubiquitin ligase that can mediate the ubiquitination of host immune effect molecules. ERGIC-53 is a type of lectin mainly located in the endoplasmic reticulum and golgi bodies.

The mechanism of *Mj*LTL2 in WSSV replication may involve the unfolded protein response (UPR). UPR is activated to alleviate ER stress \[[@bib38]\] and consists of three signaling pathways that contribute to reducing the accumulation of unfolded or misfolded proteins in the ER lumen \[[@bib39]\]. One of the UPR signal pathways is the activating transcription factor 6 (ATF6) pathway. *Lv*ATF6 significantly upregulates the expression of many WSSV genes, such as *wsv045* and *wsv343*, and could inhibit apoptosis for WSSV replication \[[@bib40]\]. As indicated by a previous study, the homolog of ATFα from *M. japonicus* is vital for WSSV replication, and UPR in *M. japonicus* may facilitate WSSV infection \[[@bib41]\]. ERGIC-53 is a target of the ATF6 pathway of UPR \[[@bib42]\]. *Pc*L-lectin, a homolog of ERGIC-53, may interact with VP24 and is required for the multiplication of WSSV \[[@bib12]\]. As a homolog of ERGIC-53, *Mj*LTL2 may be a target of *Mj*ATF6 in *M. japonicus* and participate in WSSV proliferation. The exact mechanism underlying *Mj*LTL2-WSSV replication remains unclear and must be determined in future research.
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[^1]: NI^a^: not inhibited at a concentration of 10 mg/ml.

[^2]: NI^b^: not inhibited at a concentration of 800 mmol/L.
